Cargando…

Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic

Although the introduction of stem cell transplantation and novel agents has improved survival, multiple myeloma (MM) is still difficult to cure. Alternative approaches are clearly needed to prolong the survival of patients with MM. Dendritic cell (DC) therapy is a very promising tool immunologically...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoang, My-Dung, Jung, Sung-Hoon, Lee, Hyun-Ju, Lee, Youn-Kyung, Nguyen-Pham, Thanh-Nhan, Choi, Nu-Ri, Vo, Manh-Cuong, Lee, Seung-Shin, Ahn, Jae-Sook, Yang, Deok-Hwan, Kim, Yeo-Kyeoung, Kim, Hyeoung-Joon, Lee, Je-Jung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Chonnam National University Medical School 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4406989/ https://www.ncbi.nlm.nih.gov/pubmed/25914874 http://dx.doi.org/10.4068/cmj.2015.51.1.1

Ejemplares similares

Chaetocin enhances dendritic cell function via the induction of heat shock protein and cancer testis antigens in myeloma cells
por: Vo, Manh-Cuong, et al.
Publicado: (2017)

Branched Polyethylenimine-Superparamagnetic Iron Oxide Nanoparticles (bPEI-SPIONs) Improve the Immunogenicity of Tumor Antigens and Enhance Th1 Polarization of Dendritic Cells
por: Hoang, My-Dung, et al.
Publicado: (2015)

Sarcoplasmic reticulum Ca(2+) ATPase 2 (SERCA2) reduces the migratory capacity of CCL21-treated monocyte-derived dendritic cells
por: Hong, Cheol Yi, et al.
Publicado: (2016)

Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve?
por: Nguyen-Pham, Thanh-Nhan, et al.
Publicado: (2012)

Cellular immunotherapy using dendritic cells against multiple myeloma
por: Nguyen-Pham, Thanh-Nhan, et al.
Publicado: (2012)

Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma
por: Ahn, Jae-Sook, et al.
Publicado: (2014)

Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model
por: Vo, Manh-Cuong, et al.
Publicado: (2017)

The Impact of Hyperglycemia on Risk of Severe Infections during Early Period of Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2014)

Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity
por: Vo, Manh-Cuong, et al.
Publicado: (2015)

Novel IL-15 dendritic cells have a potent immunomodulatory effect in immunotherapy of multiple myeloma
por: Chu, Tan-Huy, et al.
Publicado: (2022)

Oliguria as an early indicator of mortality risk in patients with multiple myeloma and renal impairment
por: Jung, Sung-Hoon, et al.
Publicado: (2015)

Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model
por: Vo, Manh-Cuong, et al.
Publicado: (2018)

Poor prognostic significance of Mycobacterium tuberculosis infection during bortezomib-containing chemotherapy in patients with multiple myeloma
por: Ahn, Jae-Sook, et al.
Publicado: (2013)

STAT3 expression is associated with poor survival in non-elderly adult patients with newly diagnosed multiple myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2017)

Cellular immunotherapy in multiple myeloma
por: Vo, Manh-Cuong, et al.
Publicado: (2019)

Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma
por: Vo, Manh-Cuong, et al.
Publicado: (2018)

DNA Methylation Changes Following 5-azacitidine Treatment in Patients with Myelodysplastic Syndrome
por: Tran, Huong Thi Thanh, et al.
Publicado: (2011)

Improved Therapeutic Effect against Leukemia by a Combination of the Histone Methyltransferase Inhibitor Chaetocin and the Histone Deacetylase Inhibitor Trichostatin A
por: Tran, Huong Thi Thanh, et al.
Publicado: (2013)

Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2015)

Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft model
por: Thangaraj, Jaya Lakshmi, et al.
Publicado: (2022)

Predictive Efficacy of Interim Positron Emission Tomography/Computed Tomography (PET/CT) for the Treatment of Aggressive Lymphoma
por: Yang, Deok-Hwan, et al.
Publicado: (2015)

Rituximab plus Ifosfamide, Carboplatin and Etoposide for T-Cell/Histiocyte-Rich B-Cell Lymphoma Arising in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma
por: Park, Hyung-Chul, et al.
Publicado: (2012)

OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2014)

Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients
por: Lee, Seung-Shin, et al.
Publicado: (2016)

Successful Treatment of Pure Red Cell Aplasia with Rituximab in Patients after ABO-Compatible Allogeneic Hematopoietic Stem Cell Transplantation
por: Jung, Sung-Hoon, et al.
Publicado: (2012)

Adoptive NK Cell Therapy - a Beacon of Hope in Multiple Myeloma Treatment
por: Vu, Son Hai, et al.
Publicado: (2023)

Newly Developed Multiple Myeloma in a Patient with Primary T-Cell Lymphoma of Bone
por: Hwang, Jun-Eul, et al.
Publicado: (2008)

Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen
por: Jung, Sung-Hoon, et al.
Publicado: (2016)

Prognostic significance of nucleophosmin mutations and FLT3 internal tandem duplication in adult patients with cytogenetically normal acute myeloid leukemia
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2010)

Fludarabine-containing chemotherapy for patients with previously untreated low-grade non-Hodgkin's lymphoma
por: Ahn, Jae-Sook, et al.
Publicado: (2011)

A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2017)

Frontline therapy for newly diagnosed patients with multiple myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2020)

Treatment outcome of all-trans retinoic acid/anthracycline combination chemotherapy and the prognostic impact of FLT3/ITD mutation in acute promyelocytic leukemia patients
por: Hong, Seung-Dok, et al.
Publicado: (2011)

Fatal Interstitial Pneumonitis Rapidly Developed after the First Cycle of CHOP with Etoposide Combination Chemotherapy in a Patient with Lymphoma
por: Park, Hyung Chul, et al.
Publicado: (2013)

Optimal chemo-mobilization for the collection of peripheral blood stem cells in patients with multiple myeloma
por: Song, Ga-Young, et al.
Publicado: (2019)

A Case of Disseminated and Fulminant Plasmacytomas That Developed during Bortezomib Treatment
por: Bae, Soo-Young, et al.
Publicado: (2011)

Treatment of BK virus-associated hemorrhagic cystitis with low-dose intravenous cidofovir in patients undergoing allogeneic hematopoietic cell transplantation
por: Lee, Seung-Shin, et al.
Publicado: (2015)

Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma
por: Song, Ga-Young, et al.
Publicado: (2020)

Bi-weekly Chemotherapy of Paclitaxel and Cisplatin in Patients with Metastatic or Recurrent Esophageal Cancer
por: Cho, Sang-Hee, et al.
Publicado: (2005)

Polymorphisms in DNA Repair Genes and MDR1 and the Risk for Non-Hodgkin Lymphoma
por: Kim, Hee Nam, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_o7j7ngep1nvsqf5dc0hsn8tq7o